Cartalax (20mg) is a synthetic short-peptide research material supplied as a lyophilized powder. It is intended exclusively for controlled in vitro laboratory research, analytical evaluation, and scientific experimentation.
Cartalax may be examined as a test article in cartilage-associated cellular and molecular research models. References to cartilage, connective tissue, or related biological systems describe laboratory research contexts only and do not indicate an intended physiological or therapeutic effect.
Lot-specific analytical documentation is available for researchers evaluating product identity and purity.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Cartalax (20mg) is a synthetic short-peptide research material intended exclusively for controlled in vitro laboratory research and analytical evaluation. It is supplied as a lyophilized powder and may be incorporated as a test article in experimental systems involving cartilage-associated cells, molecular markers, and biochemical pathways.
Cartalax is not intended to produce, evaluate, or substantiate health outcomes in humans or animals. References to cartilage and connective-tissue-associated systems identify potential research-model categories and do not represent claims regarding joint function, structural restoration, or clinical utility.
Cartalax (20mg) – Research Specifications:
| Compound | Cartalax |
| Quantity | 20mg per vial |
| Compound Type | Synthetic short-peptide research material |
| Appearance | Lyophilized powder |
| Purity and Identity | Refer to the lot-specific Certificate of Analysis |
| Analytical Documentation | Batch-specific documentation is available through the COA Library |
| Storage Conditions | Keep sealed in a cool, dry environment protected from heat, light, and moisture |
| Research Classification | For controlled laboratory research and analytical use only |
| Restrictions | Not for human or animal consumption, in vivo use, or diagnostic, therapeutic, veterinary, food, drug, cosmetic, or dietary supplement applications |
Cartalax is classified as a synthetic short-peptide research material. Laboratory investigations may use Cartalax as a test article when examining measurable biochemical activity in cartilage-associated cellular systems.
Research designs involving Cartalax may monitor predefined variables such as molecular-marker expression, peptide interactions, or other analytical endpoints under controlled in vitro conditions. These experimental measurements require suitable controls, validated methods, and complete documentation of test conditions.
Cartalax is supplied as a laboratory material rather than a drug, dietary supplement, cosmetic ingredient, or therapeutic product. Its availability for research does not establish safety, effectiveness, clinical utility, or suitability for human or veterinary use.
Important Research Notice: NordSci provides lot-specific analytical documentation for product identity and purity review. Researchers should consult the applicable Certificate of Analysis before incorporating the material into an experiment.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, DIAGNOSTIC, THERAPEUTIC, VETERINARY, FOOD, DRUG, COSMETIC, OR DIETARY SUPPLEMENT USE.
Cartalax may be used as an experimental test article in controlled in vitro systems containing cartilage-associated cells or selected molecular components. Researchers can document observable biochemical responses according to predefined study protocols.
This research context does not imply that Cartalax maintains, restores, or changes cartilage in humans or animals.
Controlled laboratory assays may examine Cartalax alongside selected markers associated with connective-tissue biology. Experimental variables should be defined before testing and evaluated using appropriate negative, positive, and vehicle controls where applicable.
Observed laboratory activity should not be interpreted as evidence of a physiological, restorative, or therapeutic effect.
Within joint-tissue-associated in vitro models, Cartalax may be evaluated against predetermined molecular or analytical endpoints. The term “maintenance” identifies the research category and does not constitute a claim that the material maintains joint structure or function.
Research findings from isolated cellular or biochemical models cannot independently establish human or animal outcomes.
Cartalax may be included in laboratory systems designed to measure selected extracellular-matrix-associated markers or signaling variables. Researchers should document assay conditions, material concentration, exposure parameters, controls, and analytical methods according to institutional procedures.
Any observations remain specific to the experimental model and conditions under which they were recorded.
Cartalax (20mg) should be handled by qualified laboratory personnel using established chemical-hygiene procedures and institution-approved protocols. Laboratories should document the product lot, storage conditions, handling dates, experimental parameters, and analytical methods used during each study.
Avoid exposure to heat, direct light, moisture, and cross-contamination. Laboratories should determine appropriate personal protective equipment and containment measures through their internal safety assessments.
This product is not supplied with instructions for dosing, administration, injection, ingestion, topical application, or other human or animal use.
Protocol Design Considerations: Experimental results may vary according to the selected model, assay conditions, controls, analytical method, material concentration, exposure period, and sample-handling procedures. Conclusions should remain limited to the specific controlled system evaluated.
This information is provided exclusively for qualified laboratory personnel conducting controlled research and analytical work.
Lot-specific Certificates of Analysis are available for Cartalax (20mg). The applicable COA should be reviewed for reported identity information, analytical methods, purity results, and batch traceability.
Analytical documentation relates only to the tested product lot. It does not establish approval for human or veterinary use or validate the material for diagnostic or therapeutic applications.
Laboratories sourcing Cartalax should evaluate product identity, batch traceability, storage requirements, and access to lot-specific analytical documentation.
NordSci Peptides supplies Cartalax (20mg) as a laboratory research material with corresponding batch documentation available through its COA Library.
IMPORTANT: Cartalax (20mg) is supplied exclusively for controlled laboratory research and analytical use. It is not approved for human or animal consumption or for diagnostic, therapeutic, veterinary, food, drug, cosmetic, or dietary supplement applications. Researchers are responsible for complying with all applicable institutional, local, state, and federal requirements.
Researchers should consult current peer-reviewed literature, validated analytical methods, and institution-approved protocols relevant to their specific in vitro model. Product-specific identity and purity information should be verified using the Certificate of Analysis for the applicable lot.
